Story perspectives

New Wegovy Injection Achieves 20% Weight Loss, But Cost Concerns Loom

9/15/2025

43 8

Summary

Story summary

A triple-strength Wegovy injection (7.2mg) leads to nearly 20% body weight loss, surpassing the 15.6% loss from the standard 2.4mg dose in landmark trials.
The studies included over 2,000 adults with obesity, some with type 2 diabetes, over 72 weeks.
Higher doses showed more mild side effects, such as nausea and diarrhea.
Experts express concerns about tolerability and potential low uptake due to cost.
Semaglutide has revolutionized obesity treatment but faces criticism over rising costs, with fewer than 200,000 accessing weight-loss jabs through the NHS.

1 of 1

Story summary

A triple-strength Wegovy injection (7.2mg) leads to nearly 20% body weight loss, surpassing the 15.6% loss from the standard 2.4mg dose in landmark trials.
The studies included over 2,000 adults with obesity, some with type 2 diabetes, over 72 weeks.
Higher doses showed more mild side effects, such as nausea and diarrhea.
Experts express concerns about tolerability and potential low uptake due to cost.
Semaglutide has revolutionized obesity treatment but faces criticism over rising costs, with fewer than 200,000 accessing weight-loss jabs through the NHS.